AR055608A1 - Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica - Google Patents
Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeuticaInfo
- Publication number
- AR055608A1 AR055608A1 ARP060103593A ARP060103593A AR055608A1 AR 055608 A1 AR055608 A1 AR 055608A1 AR P060103593 A ARP060103593 A AR P060103593A AR P060103593 A ARP060103593 A AR P060103593A AR 055608 A1 AR055608 A1 AR 055608A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- fluorophenyl
- ethyl
- hypnotic
- agent
- Prior art date
Links
- 230000000147 hypnotic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003326 hypnotic agent Substances 0.000 abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical class COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 abstract 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 abstract 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 abstract 1
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 1
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- CBIAWPMZSFFRGN-UHFFFAOYSA-N Indiplon Chemical compound CC(=O)N(C)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C(=O)C=2SC=CC=2)=C1 CBIAWPMZSFFRGN-UHFFFAOYSA-N 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 abstract 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 229960003051 brotizolam Drugs 0.000 abstract 1
- 229960001578 eszopiclone Drugs 0.000 abstract 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 abstract 1
- 229960004404 etizolam Drugs 0.000 abstract 1
- 229950003867 indiplon Drugs 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 239000002974 melatonin derivative Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229960001150 ramelteon Drugs 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009476 short term action Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 abstract 1
- 229960003386 triazolam Drugs 0.000 abstract 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004010 zaleplon Drugs 0.000 abstract 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001475 zolpidem Drugs 0.000 abstract 1
- 229960000820 zopiclone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Combinacion de un agente hipnotico de accion a corto plazo y de R-(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidin-metanol (compuesto A) o su profármaco que presenta la formula (2) en la que R es alquilo C1-20, o una sal suya farmacéuticamente aceptable. La combinacion de la presente es util en el tratamiento de una variedad de trastornos del sueno. Reivindicacion 3: La combinacion establecida en la reivindicacion 1, en la que el agente hipnotico de accion a corto plazo es un modulador de receptores de GABA-A, benzodiacepina, un derivado de melatonina o un agonista de receptores de melatonina. Reivindicacion 4: La combinacion establecida en la reivindicacion 1, en la que el agente hipnotico de accion a corto plazo se selecciona del grupo que consiste en zolpidem, zopiclona, eszopiclona, zaleplon, melatonina, ramelteon, triazolam, etizolam, brotizolam e indiplon, o un derivado o una mezcla suya en cualquier combinacion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70951005P | 2005-08-19 | 2005-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055608A1 true AR055608A1 (es) | 2007-08-29 |
Family
ID=37772165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103593A AR055608A1 (es) | 2005-08-19 | 2006-08-17 | Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica |
Country Status (14)
Country | Link |
---|---|
US (1) | US20080139615A1 (es) |
EP (1) | EP1937265A2 (es) |
JP (1) | JP2009504760A (es) |
KR (1) | KR20080034475A (es) |
CN (1) | CN101247810A (es) |
AR (1) | AR055608A1 (es) |
AU (1) | AU2006283702A1 (es) |
BR (1) | BRPI0615357A2 (es) |
CA (1) | CA2617975A1 (es) |
IL (1) | IL189557A0 (es) |
MX (1) | MX2008001705A (es) |
RU (1) | RU2008110477A (es) |
TW (1) | TW200815030A (es) |
WO (1) | WO2007024599A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK42499A3 (en) * | 1996-10-21 | 2000-05-16 | Neurosearch As | 1-phenyl-benzimidazole compounds and their use as gabaa receptor modulators |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
US6277864B1 (en) * | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
US20040258750A1 (en) * | 1999-06-28 | 2004-12-23 | Gerard Alaux | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
ES2277301T3 (es) * | 2000-04-24 | 2007-07-01 | Teva Pharmaceutical Industries Ltd. | Solvato de hemitartrato de zolpidem. |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
TW200626137A (en) * | 2004-12-13 | 2006-08-01 | Takeda Pharmaceuticals Co | Preventive or therapeutic agent for sleep disorder |
-
2006
- 2006-08-16 JP JP2008527114A patent/JP2009504760A/ja not_active Abandoned
- 2006-08-16 KR KR1020087003961A patent/KR20080034475A/ko not_active Application Discontinuation
- 2006-08-16 BR BRPI0615357-7A patent/BRPI0615357A2/pt not_active IP Right Cessation
- 2006-08-16 MX MX2008001705A patent/MX2008001705A/es not_active Application Discontinuation
- 2006-08-16 WO PCT/US2006/032026 patent/WO2007024599A2/en active Application Filing
- 2006-08-16 CA CA002617975A patent/CA2617975A1/en not_active Abandoned
- 2006-08-16 CN CNA2006800301572A patent/CN101247810A/zh active Pending
- 2006-08-16 EP EP06801652A patent/EP1937265A2/en not_active Withdrawn
- 2006-08-16 AU AU2006283702A patent/AU2006283702A1/en not_active Abandoned
- 2006-08-16 RU RU2008110477/15A patent/RU2008110477A/ru unknown
- 2006-08-17 AR ARP060103593A patent/AR055608A1/es unknown
- 2006-08-18 TW TW095130325A patent/TW200815030A/zh unknown
-
2008
- 2008-02-06 US US12/027,012 patent/US20080139615A1/en not_active Abandoned
- 2008-02-17 IL IL189557A patent/IL189557A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0615357A2 (pt) | 2011-05-17 |
AU2006283702A1 (en) | 2007-03-01 |
CN101247810A (zh) | 2008-08-20 |
EP1937265A2 (en) | 2008-07-02 |
RU2008110477A (ru) | 2009-09-27 |
IL189557A0 (en) | 2008-08-07 |
TW200815030A (en) | 2008-04-01 |
US20080139615A1 (en) | 2008-06-12 |
JP2009504760A (ja) | 2009-02-05 |
MX2008001705A (es) | 2008-04-07 |
WO2007024599A2 (en) | 2007-03-01 |
KR20080034475A (ko) | 2008-04-21 |
WO2007024599A3 (en) | 2007-11-22 |
CA2617975A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
MY155255A (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
PE20120413A1 (es) | ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA | |
CR8146A (es) | Metodos para tratar canceres usando formas poliformicas de 3-(4-amino -1-oxo-1,3 dihidro-isoindol-2-il)- piperidina-2,6-dione | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
ATE549021T1 (de) | Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil | |
CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
MX2020012868A (es) | Metodos y composiciones para trastornos del sue?o y otros trastornos. | |
CL2004000234A1 (es) | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
PE20060957A1 (es) | Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas | |
CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
UY30577A1 (es) | Derivados de éter diarilico y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |